NCT02033343 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Colvill E, Booth JT, O'Brien RT, Eade TN, Kneebone AB, Poulsen PR, Keall PJ
Multileaf Collimator Tracking Improves Dose Delivery for Prostate Cancer Radiation Therapy: Results of the First Clinical Trial. Int J Radiat Oncol Biol Phys. 2015 Aug 1;92(5):1141-1147. doi: 10.1016/j.ijrobp.2015.04.024. Epub 2015 Apr 17.
Colvill E, Poulsen PR, Booth JT, O'Brien RT, Ng JA, Keall PJ
DMLC tracking and gating can improve dose coverage for prostate VMAT. Med Phys. 2014 Sep;41(9):091705. doi: 10.1118/1.4892605.
Keall PJ, Colvill E, O'Brien R, Ng JA, Poulsen PR, Eade T, Kneebone A, Booth JT
The first clinical implementation of electromagnetic transponder-guided MLC tracking. Med Phys. 2014 Feb;41(2):020702. doi: 10.1118/1.4862509.

Phase I Feasibility Study of Prostate Cancer Radiotherapy Using Realtime Dynamic Multileaf Collimator Adaptation and Radiofrequency Tracking (Calypso)

Details for clinical trial NCT02033343

Clinical trial NCT02033343 - References